Abstract
The effect of treatment with melatonin was investigated in a rat model of Alzheimer’s disease (AD) involving a single intra-hippocampal injection of amyloid peptide Aβ1-42. Thirty days after this injection immunohistochemical analysis revealed significant increases of both S-100β and NFκB in cortex and hippocampus of treated animals. Levels of synaptophysin were depressed following treatment and this was confirmed by Western blotting. Histopathological studies revealed a diminution of neuronal cell number in the CA3 area of the hippocampus. Behaviorally, the rate of learning escape from electroshock using a maze box was diminished in Aβ-treated mice. Another group of Aβ treated also received an oral gavage of 0.5 mg/kg melatonin on each of the 30 days between Aβ treatment and sacrifice. The effect of this repeated melatonin exposure was to reverse Aβ-induced changes in CA3 cell number and S-100 levels. The increased cerebral content of NF-κB and the behavioral changes caused by Aβ treatment were partially reversed by melatonin. However, melatonin administration had no effect on the reduced level of synaptophysin in Aβ-treated mice. Overall, these findings suggest that melatonin may exert a potentially beneficial effect upon the progression of AD.
Keywords: Alzheimer's disease, amyloid, hippocampus, learning, melatonin, NF-κB.
Current Aging Science
Title:Melatonin Decreases Levels of S100β and NFκB, Increases Levels of Synaptophysinina Rat Model of Alzheimer's Disease
Volume: 6 Issue: 2
Author(s): Zhou Jun, Zhou Li, Wang Fang, Yang Fengzhen, Wen Puyuan, Li Wenwen, Song Zhi and Stephen C. Bondy
Affiliation:
Keywords: Alzheimer's disease, amyloid, hippocampus, learning, melatonin, NF-κB.
Abstract: The effect of treatment with melatonin was investigated in a rat model of Alzheimer’s disease (AD) involving a single intra-hippocampal injection of amyloid peptide Aβ1-42. Thirty days after this injection immunohistochemical analysis revealed significant increases of both S-100β and NFκB in cortex and hippocampus of treated animals. Levels of synaptophysin were depressed following treatment and this was confirmed by Western blotting. Histopathological studies revealed a diminution of neuronal cell number in the CA3 area of the hippocampus. Behaviorally, the rate of learning escape from electroshock using a maze box was diminished in Aβ-treated mice. Another group of Aβ treated also received an oral gavage of 0.5 mg/kg melatonin on each of the 30 days between Aβ treatment and sacrifice. The effect of this repeated melatonin exposure was to reverse Aβ-induced changes in CA3 cell number and S-100 levels. The increased cerebral content of NF-κB and the behavioral changes caused by Aβ treatment were partially reversed by melatonin. However, melatonin administration had no effect on the reduced level of synaptophysin in Aβ-treated mice. Overall, these findings suggest that melatonin may exert a potentially beneficial effect upon the progression of AD.
Export Options
About this article
Cite this article as:
Jun Zhou, Li Zhou, Fang Wang, Fengzhen Yang, Puyuan Wen, Wenwen Li, Zhi Song and Bondy C. Stephen, Melatonin Decreases Levels of S100β and NFκB, Increases Levels of Synaptophysinina Rat Model of Alzheimer's Disease, Current Aging Science 2013; 6 (2) . https://dx.doi.org/10.2174/18746098112059990005
DOI https://dx.doi.org/10.2174/18746098112059990005 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Pharmacokinetics and Toxicology of Aluminum in the Brain
Current Inorganic Chemistry (Discontinued) Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Regression of Oxidative Stress by Targeting eNOS and Nrf2/ARE Signaling: A Guided Drug Target for Cardiovascular Diseases
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Recent Patents on CNS Drug Discovery (Discontinued) Proteasome Inhibitors and Modulators of Angiogenesis in Multiple Myeloma
Current Medicinal Chemistry PACAP and Its Receptors Exert Pleiotropic Effects in The Nervous System by Activating Multiple Signaling Pathways
Current Protein & Peptide Science Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science Collective Roles of Molecular Chaperones in Protein Degradation Pathways Associated with Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry Micro-Nanomaterials for Tumor Microwave Hyperthermia: Design, Preparation, and Application
Current Drug Delivery 6-Acetyl-5H-thiazolo[3,2-a]pyrimidine Derivatives as the Novel Acetylcholinesterase Inhibitors: Design, Synthesis, and Biological Activity
Medicinal Chemistry Brain Nitric Oxide and Its Dual Role in Neurodegeneration / Neuroprotection: Understanding Molecular Mechanisms to Devise Drug Approaches
Current Medicinal Chemistry Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Current Neuropharmacology Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Current Pharmaceutical Biotechnology Applications of iTRAQ and TMT Labeling Techniques to the Study of Neurodegenerative Diseases
Current Protein & Peptide Science Co-Treatment With Copper Compounds Dramatically Decreases Toxicities Observed With Cisplatin Cancer Therapy And The Anticancer Efficacy Of Some Copper Chelates Supports The Conclusion That Copper Chelate Therapy May Be Markedly More Effective And Less Toxic Than Cisplatin Therapy
Current Medicinal Chemistry The Renin-Angiotensin System in the Mammalian Central Nervous System
Current Protein & Peptide Science The Potential for Targeting Oncogenic WNT/β -Catenin Signaling in Therapy
Current Drug Targets Prolyl Oligopeptidase, Inositol Phosphate Signalling and Lithium Sensitivity
CNS & Neurological Disorders - Drug Targets